Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy

被引:32
|
作者
Rose, April A. N. [1 ,2 ]
Armstrong, Susan M. [3 ]
Hogg, David [1 ]
Butler, Marcus O. [1 ,2 ,4 ]
Saibil, Samuel D. [1 ,2 ,4 ]
Arteaga, Diana P. [1 ,2 ]
Muniz, Thiago Pimentel [1 ,2 ]
Kelly, Deirdre [1 ,2 ]
Ghazarian, Danny [3 ,5 ]
King, Ian [3 ,5 ]
Kamil, Zaid Saeed [3 ,5 ]
Ross, Kendra [4 ]
Spreafico, Anna [1 ,2 ,4 ]
机构
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada
[2] Univ Toronto, Dept Med, Div Med Oncol, Toronto, ON, Canada
[3] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[4] Univ Hlth Network, Princess Margaret Canc Ctr, Tumor Immunotherapy Program, Toronto, ON, Canada
[5] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
关键词
melanoma; genetic markers; immunotherapy; programmed cell death 1 receptor; tumor biomarkers; TUMOR MICROENVIRONMENT; MUTANT MELANOMA; RESPONSE RATE; CLASSIFICATION; PEMBROLIZUMAB; IPILIMUMAB; REGRESSION; NIVOLUMAB; MUCOSAL; PATHWAY;
D O I
10.1136/jitc-2020-001642
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Anti-programmed cell death protein 1 (PD1)+/- anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4) immune checkpoint inhibitors (ICIs) are standard therapeutic options for metastatic melanoma. We assessed whether biologic subtype according to primary tumor type or genomic subtype can function as predictive biomarkers for anti-PD1 +/- anti-CTLA4 ICI in patients with advanced melanoma. Methods We performed a single-center retrospective cohort analysis of patients who received anti-PD1 +/- anti-CTLA4 ICI for advanced melanoma between 2012 and 2019. Primary tumor type, BRAF and NRAS mutation status, and other covariates were abstracted from chart review. Log-rank tests and multivariable Cox regression models were used to assess differences in clinical progression-free (cPFS) and overall survival (OS). Results We identified 230 patients who received 249 lines of anti-PD1 +/- anti-CTLA4 ICI for unresectable or metastatic disease. Of these patients, 74% were cutaneous, 11% mucosal, 8% unknown primary and 7% acral. BRAF and NRAS mutations were identified in 35% and 28% of patients, respectively. In multivariable analyses of the entire cohort, acral or mucosal primary tumor type, >3 metastatic sites, elevated LDH were predictive of shorter cPFS and OS. Combination ICI therapy was associated with longer cPFS (HR 0.57, 95% CI 0.38 to 0.86, p=0.007) and OS (HR 0.42, 95% CI 0.28 to 0.65, p<0.001). Combination ICI was significantly associated with longer OS in unknown primary and mucosal melanoma. There was a non-significant trend toward longer OS with anti-PD1+anti-CTLA4 in cutaneous melanoma, but not in acral melanoma. In multivariable analyses, combination ICI was associated with longer OS in NRAS (HR 0.24, 95% CI 0.10 to 0.62, p=0.003, n=69) and BRAF V600E/K (HR 0.47, 95% CI 0.24 to 0.90, p=0.024, n=86) mutant melanoma but not BRAF/NRAS wild-type (n=94) melanoma. Conclusions In our cohort, primary melanoma tumor type and genomic subtype were independent predictive markers of cPFS and OS for patients with metastatic melanoma receiving anti-PD1 ICI. Primary tumor type and genomic subtype-including NRAS-should be further evaluated in prospective clinical trials to determine their value as predictive markers. Biologic subtypes may facilitate clinical decision-making when recommending combination ICI treatment (anti-PD1 +/- anti-CTLA4) versus anti-PD1 alone for patients with metastatic melanoma.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] First-line anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy in Japanese mucosal melanoma: A retrospective, multicenter study (JMAC study)
    Nakamura, Y.
    Namikawa, K.
    Yoshikawa, S.
    Kiniwa, Y.
    Maekawa, T.
    Yamasaki, O.
    Isei, T.
    Matsushita, S.
    Nomura, M.
    Nakai, Y.
    Fukushima, S.
    Saito, S.
    Takenouchi, T.
    Tanaka, R.
    Kato, H.
    Otsuka, A.
    Matsuya, T.
    Baba, N.
    Nagase, K.
    Inozume, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S876 - S876
  • [32] Adjuvant anti-PD-1 monotherapy benefit varies across different ethnicities and melanoma subtypes
    Bai, X.
    Gerstberger, S.
    Park, B.
    Jung, S.
    Johnson, R.
    Yamazaki, N.
    Ogata, D.
    Umeda, Y.
    Li, C.
    Si, L.
    Flaherty, K.
    Nakamura, Y.
    Namikawa, K.
    Long, G. V.
    Menzies, A. M.
    Johnson, D. B.
    Sullivan, R. J.
    Boland, G.
    Guo, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S914 - S915
  • [33] Combination between a long-acting engineered cytokine (NKTR-214) and checkpoint inhibitors anti-CTLA4 or anti-PD1 in inurine tumor models
    Kantak, Seema S.
    Lee, Steve
    Addepalli, Murali
    Hoch, Ute
    Penax, Rhoneil
    Pena, Rhoneil
    Kirksey, Yolanda
    Charych, Deborah H.
    Doberstein, Stephen K.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit
    Patel, Anisha B.
    Farooq, Sahira
    Welborn, Macartney
    Amaria, Rodabe N.
    Chon, Susan Y.
    Diab, Adi
    Oliva, Isabella C. Glitza
    Huen, Auris O.
    Li, Shirley Q.
    Nelson, Kelly C.
    Pacha, Omar
    Patel, Sapna P.
    Rapini, Ronald P.
    Tawbi, Hussein A.
    Wong, Michael K.
    McQuade, Jennifer
    Davies, Michael A.
    Haydu, Lauren E.
    CANCER, 2022, 128 (05) : 975 - 983
  • [35] Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy
    Qiaoyun Tan
    Liyuan Dai
    Yanrong Wang
    Shuxia Liu
    Te Liang
    Rongrong Luo
    Shasha Wang
    Ning Lou
    Haizhu Chen
    Yu Zhou
    Qiaofeng Zhong
    Jianliang Yang
    Puyuan Xing
    Xingsheng Hu
    Yutao Liu
    Shengyu Zhou
    Jiarui Yao
    Di Wu
    Zhishang Zhang
    Le Tang
    Xiaobo Yu
    Xiaohong Han
    Yuankai Shi
    Cancer Immunology, Immunotherapy, 2022, 71 : 1681 - 1691
  • [36] Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review
    Papouin, Barbara
    Mussini, Charlotte
    De Martin, Eleonora
    Guettier, Catherine
    ANNALES DE PATHOLOGIE, 2018, 38 (06) : 338 - 351
  • [37] RORγ agonist enhances antitumor effects of immune checkpoint anti-PD1
    Gaur, Pankaj
    Verma, Vivek
    Nandre, Rahul
    Vir, Pooja
    Wang, Hua
    Kang, Baolin
    Carter, Laura
    Hu, Xiao
    Liu, Xikui
    Gupta, Seema
    Khleif, Samir
    CANCER RESEARCH, 2018, 78 (13)
  • [38] Effect of radiofrequency ablation (RFA) combined with anti-CTLA-4 and anti-PD1 in a preclinical melanoma model.
    Franco-Mahecha, Olga L.
    Christou, Anna
    Mauda-Havakuk, Michal
    Katti, Prateek
    Pritchard, William F.
    Karanian, John W.
    Wood, Bradford J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [39] Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy
    Tan, Qiaoyun
    Dai, Liyuan
    Wang, Yanrong
    Liu, Shuxia
    Liang, Te
    Luo, Rongrong
    Wang, Shasha
    Lou, Ning
    Chen, Haizhu
    Zhou, Yu
    Zhong, Qiaofeng
    Yang, Jianliang
    Xing, Puyuan
    Hu, Xingsheng
    Liu, Yutao
    Zhou, Shengyu
    Yao, Jiarui
    Wu, Di
    Zhang, Zhishang
    Tang, Le
    Yu, Xiaobo
    Han, Xiaohong
    Shi, Yuankai
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (07) : 1681 - 1691
  • [40] PHY906(YIV-906), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Immune checkpoint blockade therapy: anti-PDL1, anti-PD1, anti-PD1/CTLA4 against melanoma
    Lam, Wing
    Jiang, Zaoli
    Han, Xue
    Liu, Shwu-Huey
    Chen, Lieping
    Cheng, YungChi
    CANCER RESEARCH, 2017, 77